Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 2.74 is 620% above its 5-year average of -0.53, near the high end of its 5-year range (-2.63–3.10).
68.10% above its 12-month average of 1.63.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.05.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T22:28:49.370Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
2.74
EARNINGS PER SHARE (EPS) AVG TTM
1.63
EARNINGS PER SHARE (EPS) AVG 3Y
0.47
EARNINGS PER SHARE (EPS) AVG 5Y
-0.53
EARNINGS PER SHARE (EPS) AVG 10Y
-1.12
EARNINGS PER SHARE (EPS) AVG 15Y
-1.41
EARNINGS PER SHARE (EPS) AVG 20Y
-1.41
CURRENT VS TTM AVG
+68.10%
CURRENT VS 3Y AVG
+480.11%
CURRENT VS 5Y AVG
+620.14%
CURRENT VS 10Y AVG
+344.83%
CURRENT VS 15Y AVG
+294.91%
CURRENT VS 20Y AVG
+294.91%
TG Therapeutics, Inc.
Market Cap
$7.99B
Earnings Per Share (EPS)
2.74
TTM Avg
1.63
3Y Avg
0.47
5Y Avg
-0.53
Market Cap
$7.81B
Earnings Per Share (EPS)
-12.93
TTM Avg
-11.85
3Y Avg
-27.93
5Y Avg
-45.71
Market Cap
$7.76B
Earnings Per Share (EPS)
0.36
TTM Avg
-1.91
3Y Avg
-1.77
5Y Avg
-0.94
Market Cap
$7.63B
Earnings Per Share (EPS)
-7.22
TTM Avg
-5.90
3Y Avg
-5.40
5Y Avg
-4.39
Market Cap
$7.61B
Earnings Per Share (EPS)
2.77
TTM Avg
1.81
3Y Avg
0.99
5Y Avg
0.59
Market Cap
$7.61B
Earnings Per Share (EPS)
1.29
TTM Avg
-2.76
3Y Avg
-2.30
5Y Avg
-2.30
Market Cap
$8.38B
Earnings Per Share (EPS)
1.40
TTM Avg
-0.79
3Y Avg
-1.41
5Y Avg
-1.76
Market Cap
$7.31B
Earnings Per Share (EPS)
-3.46
TTM Avg
-2.71
3Y Avg
-2.47
5Y Avg
-2.21
Market Cap
$8.67B
Earnings Per Share (EPS)
-2.24
TTM Avg
-2.51
3Y Avg
-2.15
5Y Avg
-1.80
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) | $7.99B | 2.74 | 1.63 | 0.47 | -0.53 |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.81B | -12.93 | -11.85 | -27.93 | -45.71 |
| Caris Life Sciences, Inc. (CAI)vs › | $7.76B | 0.36 | -1.91 | -1.77 | -0.94 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.63B | -7.22 | -5.90 | -5.40 | -4.39 |
| HealthEquity, Inc. (HQY)vs › | $7.61B | 2.77 | 1.81 | 0.99 | 0.59 |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | 1.29 | -2.76 | -2.30 | -2.30 |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 1.40 | -0.79 | -1.41 | -1.76 |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.31B | -3.46 | -2.71 | -2.47 | -2.21 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | -2.24 | -2.51 | -2.15 | -1.80 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | -3.25 | -3.33 | -3.02 | -2.52 |
Trailing EPS (TTM)
$2.74
Forward EPS (Est.)
$0.97
P/E Ratio
19.1
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 3.10 |
| 2024-12-31 | 0.16 |
| 2023-12-31 | 0.09 |
| 2022-12-31 | -1.46 |
| 2021-12-31 | -2.63 |
| 2020-12-31 | -2.42 |
| 2019-12-31 | -1.96 |
| 2018-12-31 | -2.30 |
| 2017-12-31 | -1.91 |
| 2016-12-31 | -1.60 |
| 2015-12-31 | -1.38 |
| 2014-12-31 | -1.64 |
| 2013-12-31 | -0.81 |
| 2012-12-31 | -1.38 |
| 2011-12-31 | -0.44 |
| 2010-12-31 | 15.68 |
| 2009-12-31 | -111.24 |
| 2008-12-31 | -170.00 |
| 2007-12-31 | -497.55 |
| 2006-12-31 | -453.62 |
| 2005-12-31 | -1236.34 |
| 2004-12-31 | -615.64 |
| 2003-12-31 | -748.86 |
| 2002-12-31 | -347.70 |
| 2001-12-31 | -1528.59 |
| 2000-12-31 | -13339.03 |
| 1999-12-31 | -7017.54 |
| 1998-12-31 | -8750.00 |
| 1997-12-31 | -23853.21 |
| 1996-12-31 | -17391.30 |
